Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

216 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program.
Frost N, Christopoulos P, Kauffmann-Guerrero D, Stratmann J, Riedel R, Schaefer M, Alt J, Gütz S, Christoph DC, Laack E, Faehling M, Fischer R, Fenchel K, Haen S, Heukamp L, Schulz C, Griesinger F. Frost N, et al. Among authors: griesinger f. Ther Adv Med Oncol. 2021 Feb 9;13:1758835920980558. doi: 10.1177/1758835920980558. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 33613692 Free PMC article.
Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice.
Brückl WM, Reck M, Griesinger F, Schäfer H, Kortsik C, Gaska T, Rawluk J, Krüger S, Kokowski K, Budweiser S, Ficker JH, Hoffmann C, Schüler A, Laack E. Brückl WM, et al. Among authors: griesinger f. Ther Adv Med Oncol. 2021 May 6;13:17588359211012361. doi: 10.1177/17588359211012361. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 33995597 Free PMC article.
The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions.
Christopoulos P, Kluck K, Kirchner M, Lüders H, Roeper J, Falkenstern-Ge RF, Szewczyk M, Sticht F, Saalfeld FC, Wesseler C, Hackanson B, Dintner S, Faehling M, Kuon J, Janning M, Kauffmann-Guerrero D, Kazdal D, Kurz S, Eichhorn F, Bozorgmehr F, Shah R, Tufman A, Wermke M, Loges S, Brueckl WM, Schulz C, Misch D, Frost N, Kollmeier J, Reck M, Griesinger F, Grohé C, Hong JL, Lin HM, Budczies J, Stenzinger A, Thomas M. Christopoulos P, et al. Among authors: griesinger f. Eur J Cancer. 2022 Jul;170:106-118. doi: 10.1016/j.ejca.2022.04.020. Epub 2022 May 20. Eur J Cancer. 2022. PMID: 35598358
Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer.
Stratmann JA, Michels S, Hornetz S, Christoph DC, Sackmann S, Spengler W, Bischoff H, Schäfer M, Alt J, Müller A, Laack E, Kimmich M, Griesinger F, Sebastian M. Stratmann JA, et al. Among authors: griesinger f. J Cancer Res Clin Oncol. 2018 Dec;144(12):2457-2463. doi: 10.1007/s00432-018-2754-x. Epub 2018 Sep 22. J Cancer Res Clin Oncol. 2018. PMID: 30244389
A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer.
Metzenmacher M, Kopp HG, Griesinger F, Reinmuth N, Sebastian M, Serke M, Waller CF, Thomas M, Eggert J, Schmid-Bindert G, Hoiczyk M, Christoph DC, Kimmich M, Deuß B, Seifert S, Held S, Schuler M, Herold T, Breitenbuecher F, Eberhardt WEE. Metzenmacher M, et al. Among authors: griesinger f. Ther Adv Med Oncol. 2021 Mar 9;13:1758835921996506. doi: 10.1177/1758835921996506. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 34104223 Free PMC article.
Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer.
Krefting F, Basara N, Schütte W, Späth-Schwalbe E, Alt J, Thiel S, Kimmich M, Fischer JR, Kurz S, Griesinger F, Christoph DC. Krefting F, et al. Among authors: griesinger f. Oncol Res Treat. 2019;42(5):243-255. doi: 10.1159/000499321. Epub 2019 Apr 17. Oncol Res Treat. 2019. PMID: 30995666
Lung Cancer in Germany.
Frost N, Griesinger F, Hoffmann H, Länger F, Nestle U, Schütte W, Wolf J, Reck M. Frost N, et al. Among authors: griesinger f. J Thorac Oncol. 2022 Jun;17(6):742-750. doi: 10.1016/j.jtho.2022.03.010. J Thorac Oncol. 2022. PMID: 35623674 Free article. No abstract available.
216 results